Lv5
1460 积分 2025-01-14 加入
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
7天前
已完结
A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis
21天前
已完结
PDE4 inhibitor apremilast ameliorates TNBS-induced irritable bowel syndrome in mice by activating the Nrf-2 signaling pathway in enteric glial cells
24天前
已完结
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial
25天前
已完结
Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles
1个月前
已完结
The Selective NLRP3-Inflammasome Inhibitor CY-09 AmelioratesKidney Injury in Diabetic Nephropathy by Inhibiting NLRP3-inflammasome Activation
1个月前
已完结
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy
1个月前
已完结
New potential therapeutic targets of metabolic disorder–associated kidney disease and diabetic kidney disease
1个月前
已完结
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders
1个月前
已完结
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
1个月前
已完结
皖公网安备34019202002308
